WordPress database error: [Table './shroom/wp_clean_up_optimizer_ip_locations' is marked as crashed and last (automatic?) repair failed]
SELECT * FROM wp_clean_up_optimizer_ip_locations WHERE ip='44.200.101.84'

WordPress database error: [Table './shroom/wp_clean_up_optimizer_ip_locations' is marked as crashed and last (automatic?) repair failed]
SHOW FULL COLUMNS FROM `wp_clean_up_optimizer_ip_locations`

Shroom Investor 🍄 – Psychedelics Stocks Investing News & Watch List

LATEST PSYCHEDELICS STOCKS NEWS

Cybin Completes Dosing in Phase 2 Study of CYB003 for the Treatment of Major Depressive Disorder

- Topline efficacy data expected in Q4 2023 -- Preparations are underway to scale the CYB003 program to a potential Phase 3 study in early 2024 -TORONTO, October 03, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental h... Read More...

Mydecine Innovations Group Announces Expected U.K. Dual Listing Admission Date

VANCOUVER, British Columbia, Sept. 27, 2023 -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to... Read More...

Cybin Announces Agreement with Fluence to Support Scaling of EMBARK Training for CYB003 Phase 3 Trial

TORONTO, September 26, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced an agreement with Fluence, a leading continuing... Read More...

Cybin Announces Date of Annual and Special Meeting of Shareholders

TORONTO, September 21, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that its 2023 Annual and Special Meeting of Sha... Read More...

Mydecine Innovations Announces Amended Press Release Relating to the Closing of Prospectus Supplement Financing

VANCOUVER, British Columbia, Sept. 20, 2023 -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased t... Read More...

Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA

Pre-IND submission to FDA targeted for first quarter 2024 Silo partners with Kymanox for SPC-15 ENGLEWOOD CLIFFS, NJ, Sept. 20, 2023 -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that based on posi... Read More...

Mydecine Innovations Announces Closing of Prospectus Supplement Financing

VANCOUVER, British Columbia, Sept. 19, 2023 -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to... Read More...

Numinus Takes Actions to Accelerate its Path to Profitability by Focusing on Positive Cash Flow Generating Operations

The Company is ceasing operating activities at Numinus Bioscience – its non-revenue producing research lab, and is consolidating clinic operations in certain regions to enhance company performance and improve the overall client experience. Collectively, these activities are expected to save nearly C$1 million of annualized cash expenses,... Read More...

BetterLife Pharma to Host Investors Update Call on September 18, 2023

BetterLife Pharma Inc.VANCOUVER, British Columbia, Sept. 14, 2023 -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), announces that it will host an invest... Read More...

Optimi Health Celebrates Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial

VANCOUVER, British Columbia, Sept. 14, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, is pleased to see the positive and encouraging outcomes from the MAPS Phase 3 MDMA-Assisted Therapy (MDMA-AT) Clinical Trial published today on Nature Medicine. The Compan... Read More...

Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD

Investigational New Drug (IND) submission to FDA on target for Q1 2024 SPC-15, is a novel Serotonin 4 receptor agonist against stress, developed in conjunction with Columbia University ENGLEWOOD CLIFFS, NJ, Sept. 12, 2023 -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on mergi... Read More...

Optimi Health Granted Amendment to Dealer’s Licence by Health Canada to Supply Special Access Program

Optimi Health Corp.VANCOUVER, British Columbia, Sept. 07, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, proudly announced today that Health Canada has approved an amendment to the Company’s Dealer's Licence. The amendment empowers Optimi to embark on the f... Read More...

PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine) to the FDA

TORONTO, Sept. 06, 2023 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a commercial-focused specialty pharmaceutical company, is pleased to announce it has submitted a priority original Abbreviated New Drug Application (“ANDA”) for KETARX™ (racemic ketamine) to the Food and Drug Administration (“FD... Read More...

Red Light Holland Submits Permit Application to the Township of Cavan-Monaghan for the Company’s 65,000 Square Foot Mushroom Farm

Toronto, Ontario--(Newsfile Corp. - September 5, 2023) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company"), an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin t... Read More...

Optimi Health Announces Second Tranche of CAD $1,000,000 Secured for Debt Financing

VANCOUVER, British Columbia, Sept. 05, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi Health” or the “Company”), a Canadian drug research and formulation company licensed by Health Canada to manufacture psychedelic substances such as MDMA and high-quality, GMP-grade natural psilocybin, is pleased to announce it... Read More...

Cybin to Acquire Small Pharma Inc.

- All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics -- Two proprietary, advanced clinical programs in development for depression and anxiety disorders with demonstrated safety and efficacy -- Combined portfolio creates the industry's largest, most advanced, well-protected deuterated DMT pr... Read More...

Red Light Holland Psilocybin Microdosing Capsules Aimed To Be Distributed by Nubu Pharmaceuticals In Australia Pass 8 Weeks of Stability Testing By CCREST Laboratories

Red Light Holland's natural psilocybin microdosing capsules developed from psilocybin truffles grown in the Company's farm in The Netherlands, have received the results of the first completed stability tests for the capsules, confirming stability of psilocybinConfirmation of stability of psilocybin follows the previously announced complet... Read More...

Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development

TORONTO, Aug. 22, 2023 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced that it has initiated the development of a next generation formulation of... Read More...

Psyence Group Announces Closing of Private Placement & Conclusion of Loan Agreement

TORONTO, Aug. 21, 2023 -- Psyence Group Inc. (CSE:PSYG | OTCQB:PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it has issued 1,056,441 common shares at a price of CAD$0.12 per common share for gross proceeds of CAD$126,773.... Read More...

Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2023

VANCOUVER, British Columbia, Aug. 14, 2023 -- Mydecine Innovations Group (OTC: MYCOF) (FSE: 0NFA) ("Mydecine"), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, announces the financial results for the six ... Read More...

Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, August 17, 2023

VANCOUVER, BC, Aug. 9, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF) – a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Nikhil Handa, CFO, will participate in a Water Tower Research Fireside Chat on Thursday, August 17, 2023, at... Read More...

Red Light Holland Announces Happy Caps Mushroom Farm Signs Distribution Deal with Longo Brothers Fruit Markets Inc. – Longo’s

Happy Caps Mushroom Home Grow Kits will soon be available in over 135 retail stores across Canada, including Longo's 31 locations in southern Ontario.Distribution agreement to commence September 15, 2023.Happy Caps' Lion's Mane, Shiitake, and Oyster mushroom kits sell for $25-$30 (MSRP) via www.HappyCaps.ca, Amazon (both USA and Canada), ... Read More...

Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Bright Minds Biosciences-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders-- qEEG study was conducted in healthy individuals in Cohort 4 of the Multiple Ascending Dose arm of the study-- Pro... Read More...

Psyence Group Announces SEC Registration Filing with NASDAQ SPAC, Newcourt, and Signing of Amended and Restated Business Combination Agreement

VANCOUVER, British Columbia, Aug. 02, 2023 -- Psyence Group Inc. (CSE:PSYG | OTCQB: PSYGF), a clinical-stage life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being (“Psyence”), and Newcourt Acquisition Corp (“Newcourt”) (Nasdaq: NCAC), a special purpose acquisition company (“SPAC”) toda... Read More...

Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Units

TORONTO, August 01, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, announced today the pricing of its previously announced overnight ... Read More...

Red Light Holland’s Psilocybin Microdosing Homogenized Capsules Receive Finalized Certificate of Analysis by CCREST Laboratories

The natural psilocybin microdosing capsules, developed from psilocybin truffles grown in Red Light Holland's farm in The Netherlands, have received the results of the successful final tests required for a Certificate of Analysis.Finalized Certificate of Analysis indicates Red Light Holland's lab tested Truffles meets initial requirement f... Read More...

Cybin Announces Overnight Marketed Public Offering of Units

TORONTO, July 31, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that it has launched an overnight marketed pu... Read More...